MCID: ALC004
MIFTS: 68

Alcohol Abuse

Categories: Genetic diseases, Mental diseases, Rare diseases

Aliases & Classifications for Alcohol Abuse

Summaries for Alcohol Abuse

Genetics Home Reference : 26 Alcohol use disorder is a diagnosis made when an individual has severe problems related to drinking alcohol. Alcohol use disorder can cause major health, social, and economic problems, and can endanger affected individuals and others through behaviors prompted by impaired decision-making and lowered inhibitions, such as aggression, unprotected sex, or driving while intoxicated.

MalaCards based summary : Alcohol Abuse, also known as alcohol use disorder, is related to alcohol-induced mental disorder and alcoholic psychosis, and has symptoms including hangover from any alcohol or other drugs substance and hangover from alcohol. An important gene associated with Alcohol Abuse is CYP2E1 (Cytochrome P450 Family 2 Subfamily E Member 1), and among its related pathways/superpathways are Beta-Adrenergic Signaling and GABAergic synapse. The drugs Dopamine and Bupropion have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and testes, and related phenotypes are no effect and Decreased shRNA abundance

Disease Ontology : 12 A substance abuse that involves the recurring use of alcoholic beverages despite negative consequences.

Wikipedia : 77 Alcohol abuse encompasses a spectrum of unhealthy alcohol drinking behaviors, ranging from binge... more...

Related Diseases for Alcohol Abuse

Diseases in the Alcohol Abuse family:

Alcohol Sensitivity, Acute

Diseases related to Alcohol Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1332)
# Related Disease Score Top Affiliating Genes
1 alcohol-induced mental disorder 33.8 DRD2 SLC6A4
2 alcoholic psychosis 33.7 DRD2 SLC6A4
3 nonalcoholic steatohepatitis 33.7 CYP2E1 GPT SLC17A5
4 migraine with or without aura 1 31.7 CNR1 DRD2 DRD3 SLC6A4
5 methanol poisoning 31.0 ADH1C AKR1A1 CYP2E1
6 liver disease 30.6 ABCB7 CYP2E1 GGT1 GPT SLC17A5 TF
7 anxiety 30.6 BDNF CNR1 SLC6A4
8 viral hepatitis 30.4 ABCB7 GGT1 GPT SLC17A5
9 opiate dependence 30.3 DRD2 DRD3 SLC6A4
10 conduct disorder 30.2 ALDH2 DRD2 DRD4 SLC6A4
11 tobacco addiction 30.2 ALDH2 ANKK1 DRD2 SLC6A4
12 bipolar disorder 30.2 BDNF DRD2 DRD3 SLC6A4
13 bilirubin metabolic disorder 30.2 GGT1 GPT SLC17A5
14 eating disorder 30.2 BDNF CNR1 DRD2 SLC6A4
15 post-traumatic stress disorder 30.1 BDNF CNR1 DRD2 FAAH SLC6A4
16 disease of mental health 30.1 BDNF CNR1 DRD2 DRD3 DRD4 SLC6A4
17 obstructive jaundice 30.0 GGT1 GPT SLC17A5
18 pyridoxine deficiency 30.0 GPT SLC17A5
19 body mass index quantitative trait locus 11 30.0 CNR1 CYP2E1 DRD2 FAAH GGT1 GPT
20 alcoholic hepatitis 30.0 CYP2E1 GPT SLC17A5
21 cannabis abuse 30.0 BDNF CNR1
22 delusional disorder 29.9 DRD2 DRD3 DRD4
23 cocaine dependence 29.9 DRD2 DRD3 SLC6A4
24 alexithymia 29.9 ANKK1 DRD2 SLC6A4
25 fetal alcohol spectrum disorder 29.9 AKR1A1 ALDH9A1 BDNF
26 gilles de la tourette syndrome 29.8 BDNF DRD2 DRD4
27 oppositional defiant disorder 29.8 DRD2 DRD4 SLC6A4
28 generalized anxiety disorder 29.8 BDNF DRD2 SLC6A4
29 polysubstance abuse 29.8 CNR1 DRD2 DRD3 FAAH
30 alcoholic liver cirrhosis 29.8 ADH1C ALDH2 CYP2E1 SLC17A5 TF
31 heroin dependence 29.7 ANKK1 BDNF DRD2 DRD4
32 mood disorder 29.7 BDNF DRD2 DRD3 DRD4 SLC6A4
33 pathological gambling 29.7 DRD1 DRD2 DRD3 DRD4 SLC6A4
34 major depressive disorder 29.7 BDNF DRD2 DRD3 DRD4 SLC6A4
35 tardive dyskinesia 29.7 DRD2 DRD3
36 paraquat poisoning 29.7 GPT SLC17A5
37 schizophrenia 29.7 BDNF CNR1 DRD1 DRD2 DRD3 DRD4
38 antisocial personality disorder 29.7 ALDH2 ANKK1 DRD2 SLC6A4
39 liver cirrhosis 29.6 ADH1C ALDH2 CYP2E1 GGT1 GPT SLC17A5
40 drug dependence 29.6 ANKK1 BDNF CNR1 DRD2 DRD3 SLC6A4
41 kwashiorkor 29.6 GPT SLC17A5 TF
42 bipolar i disorder 29.6 BDNF DRD1 SLC6A4
43 fatty liver disease 29.6 CYP2E1 GGT1 SLC17A5
44 personality disorder 29.6 ALDH2 ANKK1 BDNF DRD2 DRD4 SLC6A4
45 schizoaffective disorder 29.6 BDNF DRD2 DRD3 SLC6A4
46 substance abuse 29.4 ABCB7 BDNF DRD2 DRD3 DRD4 GABRA2
47 substance dependence 29.2 BDNF CNR1 DRD2 DRD3 DRD4 SLC6A4
48 obsessive-compulsive disorder 29.2 BDNF DRD1 DRD2 DRD3 DRD4 SLC6A4
49 psychotic disorder 29.1 BDNF DRD1 DRD2 DRD3 DRD4 SLC6A4
50 attention deficit-hyperactivity disorder 29.0 ANKK1 BDNF DRD1 DRD2 DRD3 DRD4

Comorbidity relations with Alcohol Abuse via Phenotypic Disease Network (PDN): (show all 20)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Alcoholic Cardiomyopathy
Alcoholic Gastritis Alcoholic Hepatitis
Alcoholic Liver Cirrhosis Alcoholic Neuropathy
Alcohol-Induced Mental Disorder Cocaine Abuse
Deficiency Anemia Familial Atrial Fibrillation
Fatty Liver Disease Hepatic Encephalopathy
Hypertension, Essential Major Depressive Disorder
Pancreatitis, Hereditary Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder

Graphical network of the top 20 diseases related to Alcohol Abuse:



Diseases related to Alcohol Abuse

Symptoms & Phenotypes for Alcohol Abuse

UMLS symptoms related to Alcohol Abuse:


hangover from any alcohol or other drugs substance, hangover from alcohol

GenomeRNAi Phenotypes related to Alcohol Abuse according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.26 ABCB7 ADH1C AKR1A1 ALDH2 ALDH9A1 ANKK1
2 Decreased shRNA abundance GR00251-A-1 9.81 ALDH9A1 CYP2E1
3 Decreased shRNA abundance GR00251-A-2 9.81 ALDH9A1 CYP2E1
4 Decreased shRNA abundance GR00297-A 9.81 ABCB7 AKR1A1 ALDH9A1 CYP2E1 GABRA2
5 shRNA abundance <= 50% GR00343-S 9.36 ADH1C AKR1A1 ALDH2 ANKK1 DRD1 DRD2

MGI Mouse Phenotypes related to Alcohol Abuse:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.19 ABCB7 ADH1C AKR1A1 ALDH2 BDNF CNR1
2 behavior/neurological MP:0005386 10.18 ALDH2 BDNF CNR1 CYP2E1 DRD1 DRD2
3 growth/size/body region MP:0005378 10.13 ABCB7 ADH1C AKR1A1 ALDH2 BDNF CNR1
4 mortality/aging MP:0010768 9.86 ABCB7 ADH1C AKR1A1 ALDH2 BDNF CNR1
5 integument MP:0010771 9.85 ALDH2 ALDH9A1 BDNF CNR1 DRD1 DRD2
6 nervous system MP:0003631 9.4 ABCB7 ALDH2 BDNF CNR1 DRD1 DRD2

Drugs & Therapeutics for Alcohol Abuse

Drugs for Alcohol Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 447)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
2
Bupropion Approved Phase 4,Phase 2,Phase 1,Not Applicable 34841-39-9, 34911-55-2 444
3
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
4
Fluoxetine Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 54910-89-3 3386
5
Acamprosate Approved, Investigational Phase 4,Phase 3,Phase 2 77337-76-9 71158
6
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 60142-96-3 3446
7
Nefopam Approved, Investigational Phase 4 13669-70-0
8
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 175805 71273
9
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
10
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
11
Clonidine Approved Phase 4,Early Phase 1 4205-90-7 2803
12
Acetaminophen Approved Phase 4,Not Applicable 103-90-2 1983
13
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 616-91-1 12035
14
Cocaine Approved, Illicit Phase 4,Phase 2,Phase 1,Not Applicable 50-36-2 446220 5760
15
Lithium carbonate Approved Phase 4,Phase 3,Phase 2 554-13-2
16
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 16590-41-3 5360515
17
Topiramate Approved Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 97240-79-4 5284627
18
Paroxetine Approved, Investigational Phase 4,Phase 1,Not Applicable 61869-08-7 43815
19
Nicotine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 54-11-5 89594 942
20
Sertraline Approved Phase 4,Phase 2,Phase 1 79617-96-2 68617
21
Ondansetron Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 99614-02-5 4595
22
Citalopram Approved Phase 4,Phase 2,Phase 1,Not Applicable 59729-33-8 2771
23
Chlorzoxazone Approved Phase 4,Not Applicable 95-25-0 2733
24
Methylphenidate Approved, Investigational Phase 4,Phase 1,Early Phase 1 113-45-1 4158
25
Varenicline Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 249296-44-4 5310966
26
Dutasteride Approved, Investigational Phase 4,Not Applicable 164656-23-9 6918296 152945
27
Zonisamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68291-97-4 5734
28
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
29
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
30
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
31
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
32
Lorazepam Approved Phase 4,Phase 2 846-49-1 3958
33
Haloperidol Approved Phase 4 52-86-8 3559
34
Ribavirin Approved Phase 4,Phase 2 36791-04-5 37542
35
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
36
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
37
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
38
Disulfiram Approved Phase 4,Phase 2 97-77-8 3117
39
Methadone Approved, Illicit Phase 4,Phase 2 76-99-3 4095
40
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 52485-79-7 644073 40400
41
Naloxone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 465-65-6 5284596
42
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
43
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1 1134-47-0 2284
44
Memantine Approved, Investigational Phase 4,Phase 2 19982-08-2 4054
45
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
46
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
47
Acetylcholine Approved, Investigational Phase 4,Phase 2 51-84-3 187
48
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 99-66-1 3121
49
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 50-56-6 53477758 439302
50
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2 132539-06-1 4585

Interventional clinical trials:

(show top 50) (show all 1255)
# Name Status NCT ID Phase Drugs
1 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
2 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE) Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
3 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
4 Epidural Analgesia for Pancreatitis (Epipan Study) Unknown status NCT02126332 Phase 4
5 Protease Inhibitor vs. Raltegravir-based ART and Inflammation in HIV Infection Unknown status NCT02691065 Phase 4 Integrase Inhibitor
6 Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Unknown status NCT03018236 Phase 4 Alcohol N-acetylcysteine;Alcohol Placebo;Cocaine N-acetylcysteine;Cocaine Placebo
7 Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4 Bupropion
8 Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse Completed NCT00190957 Phase 4 Atomoxetine;placebo
9 Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence Completed NCT00223249 Phase 4 Quetiapine
10 Naltrexone Treatment of Alcohol Abuse in Schizophrenia Completed NCT00145847 Phase 4 Naltrexone or Placebo
11 Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism Completed NCT00452543 Phase 4 acamprosate;escitalopram;Placebo
12 Placebo-Controlled Cross Over Trial of Chlorzoxazone Intake Completed NCT01342341 Phase 4 Parafon Forte
13 Adolescent Family-Based Alcohol Prevention Completed NCT00858065 Phase 4
14 Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults Completed NCT00550394 Phase 4 quetiapine and placebo;Quetiapine and Topiramate
15 Treatment of Patients With Alcoholism and Attention Deficit Disorder Completed NCT00261872 Phase 4 Methylphenidate
16 Bupropion as a Smoking Cessation Aid in Alcoholics Completed NCT00044434 Phase 4 bupropion (Wellbutrin)
17 Varenicline in Drug Treatment Completed NCT01286584 Phase 4 varenicline;placebo
18 Dutasteride Treatment for the Reduction of Heavy Drinking in Men Completed NCT01758523 Phase 4 Dutasteride;sugar pill
19 Dutasteride for the Reduction of Alcohol Use in Male Drinkers Completed NCT01262287 Phase 4 Dutasteride;Placebo
20 Zonisamide vs. Placebo in the Treatment of Alcohol Dependence Completed NCT00595556 Phase 4 zonisamide;Placebo
21 Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy Completed NCT01087736 Phase 4 Topiramate
22 Citicoline for Alcohol Dependence Completed NCT02074735 Phase 4 Placebo;Citicoline
23 AID-trial Assertive Intervention After Deliberate Self-harm Completed NCT00700089 Phase 4
24 Naltrexone for Bipolar Disorder and Alcohol Dependence Completed NCT00223275 Phase 4 Naltrexone
25 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism Completed NCT00246441 Phase 4 Paroxetine;Placebo
26 Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán Completed NCT03877120 Phase 4 Dexmedetomidine 0.004 MG/ML;Diazepam Injectable Solution
27 A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room Completed NCT00457366 Phase 4 Quetiapine;Cocktail (Haloperidol, Lorazepam, Cogentin)
28 Enhancing Smoking Cessation in the Homeless Population Completed NCT01932996 Phase 4 nicotine patch plus nicotine gum/lozenge
29 Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian Ethnicity Completed NCT00957866 Phase 4 Pegylated Interferons (Peg-IFN) and Ribavirin
30 The Effects of a Parental Intervention on Electronic Media Exposure and Sleep Patterns in Adolescents Completed NCT02365025 Phase 4
31 Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
32 Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder Completed NCT00156715 Phase 4 Quetiapine
33 Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder Completed NCT00130923 Phase 4 Risperidone Long Acting;oral risperidone
34 Drug Treatment for Depressed Alcoholics (Naltrexone/Fluoxetine) Completed NCT00006204 Phase 4 naltrexone (Revia);fluoxetine (Prozac)
35 Naltrexone, Craving, and Drinking Completed NCT00006203 Phase 4 naltrexone (Revia)
36 Naltrexone Treatment of Alcohol Dependence Completed NCT00000452 Phase 4 naltrexone (Revia)
37 Behavior and Naltrexone Treatment for Alcoholics Completed NCT00000449 Phase 4 naltrexone (Revia)
38 Use of Naltrexone in a Clinical Setting Completed NCT00000445 Phase 4 naltrexone (Revia)
39 Drug Therapy for Alcohol Detoxification Completed NCT00000441 Phase 4 lorazepam (Ativan);carbamazepine (Tegretol)
40 Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder Completed NCT00572117 Phase 4 Topiramate
41 Topiramate Treatment of Problem Drinkers Completed NCT00626925 Phase 4 topiramate;placebo
42 Biomarker Study of Acamprosate in Schizophrenia Completed NCT00688324 Phase 4 Acamprosate
43 The Whole Day First Grade Program Completed NCT00257088 Phase 4
44 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Completed NCT01015586 Phase 4 Lamotrigine;Placebo
45 Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism Completed NCT00920829 Phase 4 Naltrexone 50 Mg;Placebo
46 Pharmacogenetic Response to Naltrexone For Alcohol Dependence Completed NCT00831272 Phase 4 naltrexone;Placebo
47 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder Completed NCT00721526 Phase 4 disulfiram plus lorazepam
48 Naltrexone for Heavy Drinking in Young Adults Completed NCT00568958 Phase 4 naltrexone;placebo naltrexone
49 Targeted Naltrexone for Problem Drinkers Completed NCT00369408 Phase 4 Naltrexone;placebo
50 Sertraline Pharmacotherapy for Alcoholism Subtypes Completed NCT00368550 Phase 4 Sertraline;Placebo

Search NIH Clinical Center for Alcohol Abuse

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: alcoholism

Genetic Tests for Alcohol Abuse

Anatomical Context for Alcohol Abuse

MalaCards organs/tissues related to Alcohol Abuse:

42
Brain, Liver, Testes, Heart, Bone, Breast, Kidney

Publications for Alcohol Abuse

Articles related to Alcohol Abuse:

(show top 50) (show all 2770)
# Title Authors Year
1
Accelerated aging and motor control deficits are related to regional deformation of central cerebellar white matter in alcohol use disorder. ( 30932270 )
2019
2
Hippocampal subfield CA2+3 exhibits accelerated aging in Alcohol Use Disorder: A preliminary study. ( 30904825 )
2019
3
Emotion regulation and alcohol abuse in second-generation immigrant adolescents: The protective role of cognitive reappraisal. ( 30599787 )
2019
4
Are they there yet? Linkage of patients with tuberculosis to services for tobacco cessation and alcohol abuse - a mixed methods study from Karnataka, India. ( 30709351 )
2019
5
Medicolegal Sidebar: Alcohol Abuse-Patient Safety versus Surgeon Privacy. ( 30762681 )
2019
6
The association between HTR1B gene rs13212041 polymorphism and onset of alcohol abuse. ( 30774345 )
2019
7
Trace Element Levels and Oxidant/Antioxidant Status in Patients with Alcohol Abuse. ( 30805875 )
2019
8
Detection of alcohol abuse in older patients with cancer: The integration of alcohol screening questionnaires in the comprehensive geriatric assessment. ( 30824223 )
2019
9
Alcohol Abuse and Disorder of Granulopoiesis. ( 30831129 )
2019
10
Binge eating disorder is not predictive of alcohol abuse disorders in long-term follow-up period after Roux-en-Y gastric bypass surgery. ( 30859463 )
2019
11
Asialo-transferrin: biochemical aspects and association with alcohol abuse investigation. ( 30890358 )
2019
12
Anti-alcohol abuse drug disulfiram inhibits human PHGDH via disruption of its active tetrameric form through a specific cysteine oxidation. ( 30894617 )
2019
13
The introduction of the practice nurse mental health in general practices in the Netherlands: effects on number of diagnoses of chronic and acute alcohol abuse. ( 30940080 )
2019
14
A PDGFRβ-based score predicts significant liver fibrosis in patients with chronic alcohol abuse, NAFLD and viral liver disease. ( 31036530 )
2019
15
Function and Mechanism of Myelin Regulation in Alcohol Abuse and Alcoholism. ( 31094014 )
2019
16
Risky Drinking Decisions: The Influence of Party Music and Alcohol Abuse in Young Adult Women. ( 31100366 )
2019
17
Is the National Institute on Alcohol Abuse and Alcoholism Screening Guide Useful for Identifying Adolescents at Risk for Later Cigarette Smoking? A Prospective Study in Primary Care Clinics. ( 30273256 )
2019
18
The relationship between alcohol abuse and suicide risk according to smoking status: A cross-sectional study. ( 30342376 )
2019
19
The effect of donor alcohol abuse on outcomes following heart transplantation. ( 30536743 )
2019
20
Heterogeneous Dose-Response Analyses of Alcohol Abuse and Dependence. ( 30556903 )
2019
21
Anxiety and depression in alcohol use disorder individuals: the role of personality and coping strategies. ( 30973041 )
2019
22
Explaining the association between anxiety disorders and alcohol use disorder: A twin study. ( 30838764 )
2019
23
Treatment engagement mediates the links between symptoms of anxiety, depression, and alcohol use disorder with abstinence among smokers registered on an Internet cessation program. ( 30665605 )
2019
24
Longitudinal association between social anxiety disorder and incident alcohol use disorder: results from two national samples of US adults. ( 30054643 )
2019
25
Thiamine for preventing dementia development among patients with alcohol use disorder: A nationwide population-based cohort study. ( 29843940 )
2019
26
A Behavioral Health Program for Alcohol Use Disorder, Substance Abuse, and Depression in Chronic Liver Disease. ( 31061953 )
2019
27
Maternal half-sibling families with discordant fathers: a contrastive design assessing cross-generational paternal genetic transmission of alcohol use disorder, drug abuse and major depression. ( 30992087 )
2019
28
Effectiveness of psychological treatments for depression and alcohol use disorder delivered by community-based counsellors: two pragmatic randomised controlled trials within primary healthcare in Nepal. ( 30678744 )
2019
29
Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder. ( 30624551 )
2019
30
Executive Functioning Moderates Responses to Appetitive Cues: A Study in Severe Alcohol Use Disorder and Alcoholic Liver Disease. ( 30576416 )
2019
31
Therapeutic Approaches for NOP Receptor Antagonists in Neurobehavioral Disorders: Clinical Studies in Major Depressive Disorder and Alcohol Use Disorder with BTRX-246040 (LY2940094). ( 30701317 )
2019
32
Genetically Informative Mediation Modeling Applied to Stressors and Personality-Disorder Traits in Etiology of Alcohol Use Disorder. ( 30536213 )
2019
33
Dissociating thalamic alterations in alcohol use disorder defines specificity of Korsakoff's syndrome. ( 30879030 )
2019
34
Thiamine Substitution in Alcohol Use Disorder: A Narrative Review of Medical Guidelines. ( 30897571 )
2019
35
Cost-effectiveness of individual versus group female-specific cognitive behavioral therapy for alcohol use disorder. ( 30898323 )
2019
36
The Association Between Negative Trauma-Related Cognitions and Pain-Related Functional Status Among Veterans With Posttraumatic Stress Disorder and Alcohol Use Disorder. ( 30913347 )
2019
37
A study on the correlates of habit-, reward-, and fear-related motivations in alcohol use disorder. ( 30915941 )
2019
38
Mortality, cause of death and risk factors in patients with alcohol use disorder alone or poly-substance use disorders: a 19-year prospective cohort study. ( 30922325 )
2019
39
Effectiveness of a drinking-reduction program on drinking behavior, stages of change, drinking refusal self-efficacy, and resilience in Koreans with moderate alcohol use disorder. ( 30927989 )
2019
40
PCSK9 is Increased in Cerebrospinal Fluid of Individuals With Alcohol Use Disorder. ( 30933362 )
2019
41
Alcohol use disorder and health-related quality of life in Korean night-shift workers: A cross-sectional study using the KNHANES 2007-2015 data. ( 30933996 )
2019
42
Microstructural White Matter Alterations in Men With Alcohol Use Disorder and Rats With Excessive Alcohol Consumption During Early Abstinence. ( 30942831 )
2019
43
Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial. ( 30951210 )
2019
44
The training game SALIENCE for the therapy of alcohol use disorder. ( 30958081 )
2019
45
Respective influence of current alcohol consumption and duration of heavy drinking on brain morphological alterations in alcohol use disorder. ( 30963660 )
2019
46
Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial. ( 30977770 )
2019
47
Alterations in White Matter Microstructure and Connectivity in Young Adults with Alcohol Use Disorder. ( 30977902 )
2019
48
Assessing the collective utility of multiple analyses on clinical alcohol use disorder data. ( 30990526 )
2019
49
Studying alcohol use disorder using Drosophila melanogaster in the era of 'Big Data'. ( 30992041 )
2019
50
The Degree of Multidimensional Severity of Alcohol Use Disorder among Treatment-Seeking Patients: Is There an Additive Effect of Parental Alcohol Use Disorder? ( 30999312 )
2019

Variations for Alcohol Abuse

Expression for Alcohol Abuse

LifeMap Discovery
Genes differentially expressed in tissues of Alcohol Abuse patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 ADAMTS18 ADAM metallopeptidase with thrombospondin type 1 motif, 18 Brain - 3.66 0.005
Search GEO for disease gene expression data for Alcohol Abuse.

Pathways for Alcohol Abuse